Testing effectiveness (Phase 2)Active Not RecruitingNCT03213704
What this trial is testing
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor+30 more
National Cancer Institute (NCI) 9